Legend Biotech (LEGN) Net Equity Issued and Repurchased (2022 - 2023)

Legend Biotech (LEGN) has 4 years of Net Equity Issued and Repurchased data on file, last reported at $114.9 million in Q3 2023.

• Quarterly Net Equity Issued and Repurchased fell 69.58% year-over-year to $114.9 million in Q3 2023, while the trailing twelve-month figure through Sep 2024 was $870.2 million (down 27.1% YoY) and the FY2022 annual result came in at $377.6 million, up 16.76% from the prior year.
• Net Equity Issued and Repurchased slipped to $114.9 million in Q3 2023, from $377.6 million in the prior quarter.
• In the past five years, Net Equity Issued and Repurchased ranged from a high of $450.1 million in Q4 2020 to a low of $114.9 million in Q3 2023.
• A 4-year average of $328.7 million and a median of $377.6 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• Annual changes were most pronounced in 2022 — Net Equity Issued and Repurchased rose 16.76% — and 2023, when it slumped 69.58%.
• Tracing LEGN's Net Equity Issued and Repurchased over 4 years: stood at $450.1 million in 2020, then retreated by 28.14% to $323.4 million in 2021, then climbed by 16.76% to $377.6 million in 2022, then slumped by 69.58% to $114.9 million in 2023.
• The last three Net Equity Issued and Repurchased figures came in at $114.9 million (Q3 2023), $377.6 million (Q4 2022), and $377.6 million (Q3 2022), per Business Quant data.